TY - JOUR T1 - Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model JF - Anticancer Research JO - Anticancer Res SP - 1699 LP - 1703 DO - 10.21873/anticanres.13275 VL - 39 IS - 4 AU - RACHEL A. CROSSLEY AU - ALYSSA MATZ AU - TERRY DEW AU - ASHLEY KALINAUSKAS AU - NICOLE FAUCETTE AU - BRAD POFF AU - LAWRENCE K. SILBART AU - MARK A. SUCKOW Y1 - 2019/04/01 UR - http://ar.iiarjournals.org/content/39/4/1699.abstract N2 - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer. ER -